Vesta Therapeutics, Inc.

Cell therapeutics for liver repair and regeneration

Vesta Therapeutics is a portfolio company of Toucan Capital Corp., an investor in regenerative medicine. Vesta Therapeutics is developing therapies for repair and regeneration of liver and other major organs and acquired its technology platform in 2002 by the acquistion of Incara Cell Technologies Inc. Vesta Therapeutics, Inc. cooperates with researchers in the Cell and Molecular Physiology Department and the Division of Transplantation in the Department of Surgery at the University of North Carolina at Chapel Hill School of Medicine.

Mark Johnston, President
Joseph C. Ruiz, Ph.D., Director, Research and Development
Andrew S. Mullins, BMS, MBA, CPTC, Manager, OPO/Tissue Bank Relations

Suite 8, 801 Capitola Drive
Durham, NC 27713
USA
Phone: :+1-919-433-1900
Fax: +1-919-433-1901

Development of proprietary methods of isolating, characterising and manufacturing human hepatocytes directly from liver tissue. These hepatocytes have been accepted by the FDA for use in early stage clinical trials. The company is also developing methods to expand and differentiate hepatic progenitor cells. Vesta’s “Cell Products for Researchers Programme” offers hepatocytes, total RNA, and microsomes to other researchers.

The FDA has allowed the company’s Investigational New Drug (IND) application for a phase I clinical trial of cryopreserved, allogenic human liver cells for the treatment of patients with cirrhosis and end-stage liver disease.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.